Epidemiology and effect of psychiatric comorbidities on survival rates in patients with systemic sclerosis: A nationwide population-based cohort study.

BACKGROUND Systemic sclerosis (SSc) is a chronic, disabling connective tissue disease with a considerable psychological burden. While studies suggest a higher prevalence of psychiatric disorders in SSc, most have small sample sizes. METHODS Using Taiwan's National Health Insurance Research Database, we identified 3270 SSc patients from the catastrophic illness registry and matched them 1:4 by age and sex with 13,080 controls. We compared the incidence rate ratios (IRRs) of new psychiatric disorder diagnoses between the two groups and analyzed risk factors using a Cox proportional hazards model. Kaplan-Meier analysis and log-rank test were used to compare survival in SSc patients with and without psychiatric conditions (matched at a 1:4 ratio by age, sex and CCI). We compared psychiatric disorder incidence rates. RESULTS The SSc group had a significantly higher incidence of psychiatric disorders than controls (IRR = 1.66, p < 0.001). In SSc patients, treatment with an oral daily steroid dose of ≥7.5 mg (hazard ratio [HR] = 1.71, p = 0.010), intravenous steroid pulse therapy (HR = 2.34, p < 0.0042), or D-penicillamine (HR = 1.60, p < 0.001) served as an independent risk factor for psychiatric comorbidities. SSc patients with psychiatric comorbidities had significantly lower survival rates than those without. CONCLUSIONS Patients with SSc are at an increased risk of psychiatric comorbidities, which can negatively affect their survival rates. Treatment with a daily oral steroid dose of ≥7.5 mg, intravenous steroid pulse therapy, or D-penicillamine is a risk factor for psychiatric comorbidities in SSc.

• Publication year

  2025

• Venue

  Journal of Affective Disorders

• Publication date

  2025-04-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.jad.2025.04.104PMID 40274124
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adverse Events with d-penicillamine Therapy in Hepatic Wilson’s Disease: A Single-Center Retrospective Audit

  2022cited by this paper
• The Hospital Anxiety and Depression Scale in patients with systemic sclerosis: a psychometric and factor analysis in a monocentric cohort.

  2021cited by this paper
• One year in review 2021: systemic sclerosis.

  2021cited by this paper
• Association of Depression With All-Cause and Cardiovascular Disease Mortality Among Adults in China.

  2020cited by this paper
• Common Causes of Pain in Systemic Sclerosis: Frequency, Severity, and Relationship to Disease Status, Depression, and Quality of Life.

  2019cited by this paper
• 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

  2019cited by this paper
• The burden of depression in systemic sclerosis patients: a nationwide population-based study.

  2019cited by this paper
• Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients With Systemic Sclerosis.

  2019cited by this paper
• The association of fatigue, pain, depression and anxiety with work and activity impairment in immune mediated inflammatory diseases

  2018cited by this paper
• Addressing overestimation of the prevalence of depression based on self-report screening questionnaires

  2018cited by this paper
• Systemic sclerosis.

  2017cited by this paper
• Prevalence and Severity of Depression and Anxiety in Patients With Systemic Sclerosis: An Epidemiologic Survey and Investigation of Clinical Correlates

  2017cited by this paper
• Major Depression Diagnoses Among Patients With Systemic Sclerosis: Baseline and One‐Month Followup

  2015cited by this paper
• Depression and cardiovascular disease: a clinical review.

  2014cited by this paper
• Clinical, Functional and Health-Related Quality of Life Correlates of Clinically Significant Symptoms of Anxiety and Depression in Patients with Systemic Sclerosis: A Cross-Sectional Survey

  2014cited by this paper
• In Systemic Sclerosis, Anxiety and Depression Assessed by Hospital Anxiety Depression Scale Are Independently Associated with Disability and Psychological Factors

  2013cited by this paper
• Penicillamine Revisited: Historic Overview and Review of the Clinical Uses and Cutaneous Adverse Effects

  2013cited by this paper
• Sleep quality in patients with systemic sclerosis: relationship between the clinical variables, depressive symptoms, functional status, and the quality of life

  2013cited by this paper
• Prevalence of current, 12-month and lifetime major depressive disorder among patients with systemic sclerosis.

  2013cited by this paper
• Disease-related and psychosocial factors associated with depressive symptoms in patients with systemic sclerosis, including fear of progression and appearance self-esteem.

  2012cited by this paper
• Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies.

  2012cited by this paper
• Psychiatric Symptoms and Quality of Life in Systemic Sclerosis

  2012cited by this paper
• Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis.

  2011cited by this paper
• Low prevalence of major depressive disorder in Taiwanese adults: possible explanations and implications

  2011cited by this paper
• Mood and anxiety disorders in systemic sclerosis patients.

  2011cited by this paper
• Association of Gender with Clinical Expression, Quality of Life, Disability, and Depression and Anxiety in Patients with Systemic Sclerosis

  2011cited by this paper
• Psychiatric complications of treatment with corticosteroids: Review with case report

  2011cited by this paper
• Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database

  2010cited by this paper
• The interface of pain and mood disturbances in the rheumatic diseases.

  2010cited by this paper
• Depression in patients with systemic sclerosis: a systematic review of the evidence.

  2007cited by this paper
• Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

  2006cited by this paper
• Correlates of depression, including overall and gastrointestinal functional status, among patients with systemic sclerosis.

  2005cited by this paper
• Evaluation of depression and anxiety in patients with systemic sclerosis.

  2005cited by this paper
• Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales.

  2004cited by this paper
• Sertraline Treatment of Mood Disorder Associated with Prednisone: A Case Report

  1998cited by this paper
• Depressive symptoms associated with scleroderma.

  1996cited by this paper
• Dopamine D2 receptor binding and cerebral glucose metabolism recover afterd-penicillamine-therapy in Wilson's disease

  1994cited by this paper
• Dopamine D2 receptor binding and cerebral glucose metabolism recover after D-penicillamine-therapy in Wilson's disease.

  1994cited by this paper
• Time-dependent coefficients in a Cox-type regression model

  1991cited by this paper
• Presynaptic effects of glucocorticoids on dopaminergic and cholinergic synaptosomes. Implications for rapid endocrine-neural interactions in stress.

  1987cited by this paper
• Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy.

  1987cited by this paper
• A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

  1987cited by this paper
• Systemic sclerosis.

  1968cited by this paper

• No citing papers are available for this paper.